<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26662">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01783015</url>
  </required_header>
  <id_info>
    <org_study_id>B1801355</org_study_id>
    <nct_id>NCT01783015</nct_id>
  </id_info>
  <brief_title>Study of Etanercept in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Adalimumab or Infliximab Plus Methotrexate</brief_title>
  <acronym>SERUM</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Etanercept in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Adalimumab or Infliximab Plus Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The first 12 weeks of this study will compare the efficacy of etanercept 50 mg once-weekly
      to placebo in subjects with rheumatoid arthritis who have not responded well to infliximab
      or adalimumab plus methotrexate.  This comparison will be performed for all subjects and
      separately for subjects who are anti-drug antibody positive for one of these medications.
      From week 12 to week 24, all subjects will receive etanercept 50 mg once-weekly.  The effect
      of anti-drug antibody status on  the efficacy of etanercept as well as the safety profile of
      etanercept in these subjects will also be evaluated throughout the study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from Baseline in Disease Activity Score Based on 28-joints Count (DAS28)</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>DAS28 calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 28 joints count, the c-reactive protein (CRP) and Subject's General Health VAS assessment(participant rated health assessment with scores ranging 0 to 100; higher scores indicate worse health status).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Disease Activity Score Based on 28-joints Count (DAS28)</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>DAS28 calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 28 joints count, the c-reactive protein (CRP) and ubject General Health as measured on a 0 to 100 mm Visual Analog Scale (VAS), with 0 mm = very well and 100 mm = extremely bad</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with DAS28 &lt;3.2</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>DAS28 &lt;3.2 = low disease activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with DAS28 &lt;2.6</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>DAS28 &lt;2.6 = remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Acheiving American College of Rheumatology 20% (ACR20) Response</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>ACR20 response: greater than or equal to (≥) 20 percent (%) improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of the 5 remaining ACR core measures: 1) physician's global assessment of disease activity, 2) subject's global assessment, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire (HAQ), and 5) C-reactive protein (CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving American College of Rheumatology 50% (ACR50) Response</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>ACR50 response: greater than or equal to (≥) 50 percent (%) improvement in tender or swollen joint counts and ≥ 50% improvement in 3 of the 5 remaining ACR core measures: 1) physician's global assessment of disease activity, 2) subject's global assessment, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire (HAQ), and 5) C-reactive protein (CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving American College of Rheumatology 70% (ACR70) Response</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>ACR70 response: greater than or equal to (≥) 70 percent (%) improvement in tender or swollen joint counts and ≥ 70% improvement in 3 of the 5 remaining ACR core measures: 1) physician's global assessment of disease activity, 2) subject's global assessment, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire (HAQ), and 5) C-reactive protein (CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving American College of Rheumatology 90% (ACR90) Response</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>ACR90 response: greater than or equal to (≥) 90 percent (%) improvement in tender or swollen joint counts and ≥ 90% improvement in 3 of the 5 remaining ACR core measures: 1) physician's global assessment of disease activity, 2) subject's global assessment, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire (HAQ), and 5) C-reactive protein (CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Acheiving European League against Rheumatism (EULAR) Good and/or Moderate Response</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Acheiving Low Disease Activity or Remission Based on Clinical Disease Activity Index (CDAI)</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Acheiving Low Disease Activity or Remission Based on Simplified Disease Activity Index (SDAI)</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Clinical Disease Activity Index (CDAI)</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Simplified Disease Activity Index (SDAI)</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Number of Tender/Painful Joints</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of Tender/Painful Joints using the 28 joint count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Number of Swollen Joints</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of Swollen Joints using the 28 joint count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Physician Global Assessment (PGA) of Disease Activity</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Physician Global Assessment of Disease Activity a 0 to 10 scale, with 0 = no disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Subject Global Assessment of Disease Activity</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subject Global Assessment of Disease Activity as measured on a 0 to 10 scale, with 0 = no disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Subject General Health</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subject General Health as measured on a 0 to 100 mm Visual Analog Scale (VAS), with 0 mm = very well and 100 mm = extremely bad.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Subject Pain</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subject Pain as measured on a 0 to 100 mm Visual Analog Scale (VAS), with 0 mm = no pain and 100 mm = most severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in C-Reactive Protein (CRP)</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Health Assessment Questionnaire Disability and Discomfort Scales (HAQ-DI)</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Euro Qol EQ-5 Dimensions Questionnaire (EQ-5D)</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Short Form-36 Health Survey (SF-36)</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Patient Acceptable Symptom State (PASS)</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Vectra disease activity (DA) levels</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Positive Etanercept Anti-drug Antibody Status</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Positive Etanercept Neutralizing Anti-drug Antibody Status</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who are mAb ADA positive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who are mAb ADA negative</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects who are mAb ADA positive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects who are mAb ADA negative</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>Etanercept 50 mg once-weekly</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etnaercept</intervention_name>
    <description>Etanercept 50 mg once-weekly</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Etanercept placebo once-weekly</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Etanercept placebo once-weekly</description>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Met the 1987 ACR Revised Criteria for RA

          2. A history of inadequate response to infliximab or adalimumab in combination with
             methotrexate.

          3. A stable dose of oral methotrexate for at least 6 weeks before the baseline visit.

        Exclusion Criteria:

          1. ACR functional class IV

          2. Prior treatment with etanercept; both infliximab and adalimumab; or any
             immunosuppressive biologic agent other than infliximab or adalimumab.

          3. Discontinuation of infliximab or adalimumab for a primary reason other than
             inadequate efficacy response.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Private Rooms of Dr Anthony Boers</name>
      <address>
        <city>Morwell</city>
        <state>Victoria</state>
        <zip>3840</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>RK Will Pty Ltd</name>
      <address>
        <city>Victoria Park</city>
        <state>Western Australia</state>
        <zip>6100</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc / Service de Rhumatologie</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitares-Mont Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tseung Kwan O Hospital</name>
      <address>
        <city>Tseung Kwan O</city>
        <state>New Territories</state>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tuen Mun Hospital</name>
      <address>
        <city>Tuen Mun, NT</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pok Oi Hospital</name>
      <address>
        <city>Yuen Long, NT</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bnai Zion Medical Ctr</name>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Reade (Jan Van Breemen Instituut (JBI))</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord Holland</state>
        <zip>1056 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LLC Research Medical Complex Your Health</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan, Respublika</state>
        <zip>420097</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LLC &quot;Alliance Biomedical-Russian Group&quot;</name>
      <address>
        <city>Izhevsk</city>
        <zip>426064</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>GOU VPO Krasnoyarsk State Med Univ</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>GOU VPO Moscow SU of Medicine &amp; Dentistry ba</name>
      <address>
        <city>Moscow</city>
        <zip>127473</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Scientific Institute of Rheumatology of Russian Academy of Medical Science</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #40</name>
      <address>
        <city>Moscow</city>
        <zip>129301</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>FSBI Scientific and Research Institution of</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630117</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Basurto</name>
      <address>
        <city>Bilbao</city>
        <state>Vizcaya</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Xerencia de Xestión Integrada A Coruña, Hospital Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i San Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>H.G.U. G. Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario Carlos Haya. Hospital Civil.</name>
      <address>
        <city>Málaga</city>
        <zip>29009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>H.U.V. Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Luisa</name>
      <address>
        <city>Sevilla</city>
        <zip>41010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Hong Kong</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1801355&amp;StudyName=Study%20of%20Etanercept%20in%20Subjects%20with%20Rheumatoid%20Arthritis%20Who%20Have%20Had%20an%20Inadequate%20Response%20to%20Adalimumab%20or%20Infliximab%20Plus%20Methotrex</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>January 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>etanercept</keyword>
  <keyword>methotrexate</keyword>
  <keyword>infliximab</keyword>
  <keyword>adalimumab</keyword>
  <keyword>anti-drug antibody</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>TNFR-Fc fusion protein</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
